Mesoblast's high-risk programs drive inflated valuation. Find out why MESO stock remains a "sell" as execution risks outweigh ...

Experts have finally ended the debate about steroid shots for the back pain in the new study.According to HealthDay, ...

Scientists have developed a new systematic review to summarize for neurologists and other clinicians the evidence for epidural steroid injections and whether they reduce pain and disability for people ...